SequelSEC

MAIA Biotechnology, Inc. MAIA

Pharmaceutical Preparations · CIK 0001878313 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2024-12-31
Operating income
-$16.96M
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

MAIA Biotechnology, Inc. (MAIA) reported revenue of $0 and net income of -$23.25M for the fiscal year ended 2024-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from MAIA Biotechnology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MAIA Biotechnology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-31
Revenue$0$0$0
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$16.96M-$20.18M-$16.18M
Net income-$23.25MUnavailableUnavailable
Research & development$10.01M$11.11M$8.93M
Weighted-average diluted sharesshares 22.20Mshares 13.26Mshares 9.28M
Pretax income-$23.25M-$19.80M-$15.80M
Income tax expense$2.00KUnavailableUnavailable
Diluted EPS$-1.05$-1.49$-1.75
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$6.95M$9.07M$6.14M
Selling & marketingUnavailableUnavailableUnavailable

Balance

MAIA Biotechnology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-31
Cash & equivalents$0$0$0
Total assets$10.16M$7.57M$12.02M
Current assets$10.15M$7.56M$11.81M
Total liabilities$6.52M$7.09M$3.51M
Current liabilities$3.83M$4.94M$3.27M
Total equity incl. NCI$3.63M$477.51K$8.51M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$1.51M$1.64M$1.17M

Cash flow

MAIA Biotechnology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-31
Operating cash flow-$15.70M-$13.07M-$12.10M
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailable
Financing cash flow$18.18M$9.27M$12.48M
Net change in cash$2.45M-$3.80M$376.64K
Stock-based compensation$1.91M$3.09M$2.32M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

MAIA Biotechnology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio2.65x1.53x3.61x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MAIA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.